Tags

Type your tag names separated by a space and hit enter

Comparative effects of continuous combined hormone therapy and tibolone on body composition in postmenopausal women.
Climacteric. 2010 Jun; 13(3):249-53.C

Abstract

OBJECTIVE

To compare the effects of tibolone with those of continuous combined hormone replacement therapy (HT) on body composition in postmenopausal women.

METHODS

One hundred and fifty postmenopausal women were enrolled in a randomized, controlled trial to compare the effects of tibolone with continuous combined HT on body composition. Patients were randomly allocated into three groups and followed for 9 months. Of the subjects included, 50 women received 2.5 mg tibolone plus one Cal+D tablet (500 mg calcium and 200 IU vitamin D) daily, 50 women received 0.625 mg conjugated equine estrogen and 2.5 mg medroxyprogesterone acetate (CEE/MPA) plus one Cal+D tablet daily, and the rest (50 women) received only one Cal+D tablet and served as a control group. Body composition was evaluated with measurements of body mass index (BMI), weight, waist-to-hip ratio (WHR), fat mass and fat-free mass (FFM) before and after the intervention. Measurements of body fat mass percentage, fat mass, body fat-free mass percentage and fat-free mass (FFM) were assessed by measurement of skin-fold thickness.

RESULTS

Tibolone significantly increased weight, BMI and FFM and decreased WHR after the treatment in comparison with baseline (p < 0.05). However, only weight and BMI increased significantly in the CEE/MPA group after the treatment (p < 0.05). There were significant increases in weight, BMI and fat mass in the control group after 9 months. In the comparison of the parameters after the treatment between the three groups, tibolone significantly increased FFM compared with the control and CEE/MPA groups (p < 0.01).

CONCLUSIONS

The effect of tibolone on body composition is favorable and therefore tibolone may be regarded as an alternative to continuous combined hormone therapy in postmenopausal women.

Authors+Show Affiliations

Department of Obstetrics & Gynecology, Tarbiat Modares University, Tehran, Iran.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

19848555

Citation

Ziaei, S, et al. "Comparative Effects of Continuous Combined Hormone Therapy and Tibolone On Body Composition in Postmenopausal Women." Climacteric : the Journal of the International Menopause Society, vol. 13, no. 3, 2010, pp. 249-53.
Ziaei S, Moaya M, Faghihzadeh S. Comparative effects of continuous combined hormone therapy and tibolone on body composition in postmenopausal women. Climacteric. 2010;13(3):249-53.
Ziaei, S., Moaya, M., & Faghihzadeh, S. (2010). Comparative effects of continuous combined hormone therapy and tibolone on body composition in postmenopausal women. Climacteric : the Journal of the International Menopause Society, 13(3), 249-53. https://doi.org/10.3109/13697130903318240
Ziaei S, Moaya M, Faghihzadeh S. Comparative Effects of Continuous Combined Hormone Therapy and Tibolone On Body Composition in Postmenopausal Women. Climacteric. 2010;13(3):249-53. PubMed PMID: 19848555.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparative effects of continuous combined hormone therapy and tibolone on body composition in postmenopausal women. AU - Ziaei,S, AU - Moaya,M, AU - Faghihzadeh,S, PY - 2009/10/24/entrez PY - 2009/10/24/pubmed PY - 2010/8/19/medline SP - 249 EP - 53 JF - Climacteric : the journal of the International Menopause Society JO - Climacteric VL - 13 IS - 3 N2 - OBJECTIVE: To compare the effects of tibolone with those of continuous combined hormone replacement therapy (HT) on body composition in postmenopausal women. METHODS: One hundred and fifty postmenopausal women were enrolled in a randomized, controlled trial to compare the effects of tibolone with continuous combined HT on body composition. Patients were randomly allocated into three groups and followed for 9 months. Of the subjects included, 50 women received 2.5 mg tibolone plus one Cal+D tablet (500 mg calcium and 200 IU vitamin D) daily, 50 women received 0.625 mg conjugated equine estrogen and 2.5 mg medroxyprogesterone acetate (CEE/MPA) plus one Cal+D tablet daily, and the rest (50 women) received only one Cal+D tablet and served as a control group. Body composition was evaluated with measurements of body mass index (BMI), weight, waist-to-hip ratio (WHR), fat mass and fat-free mass (FFM) before and after the intervention. Measurements of body fat mass percentage, fat mass, body fat-free mass percentage and fat-free mass (FFM) were assessed by measurement of skin-fold thickness. RESULTS: Tibolone significantly increased weight, BMI and FFM and decreased WHR after the treatment in comparison with baseline (p < 0.05). However, only weight and BMI increased significantly in the CEE/MPA group after the treatment (p < 0.05). There were significant increases in weight, BMI and fat mass in the control group after 9 months. In the comparison of the parameters after the treatment between the three groups, tibolone significantly increased FFM compared with the control and CEE/MPA groups (p < 0.01). CONCLUSIONS: The effect of tibolone on body composition is favorable and therefore tibolone may be regarded as an alternative to continuous combined hormone therapy in postmenopausal women. SN - 1473-0804 UR - https://www.unboundmedicine.com/medline/citation/19848555/Comparative_effects_of_continuous_combined_hormone_therapy_and_tibolone_on_body_composition_in_postmenopausal_women_ L2 - https://www.tandfonline.com/doi/full/10.3109/13697130903318240 DB - PRIME DP - Unbound Medicine ER -